

REMARKS

With entry of this amendment, the status of the claims is as follows:

Original: 4, 6, 9 and 11
Currently amended: 1, 3, 5, 7 and 8
Previously presented: None
Canceled: 2, 10 and 12
Withdrawn: None
New: 13 and 14

With entry of this amendment, claims 1-9, 11, 13 and 14 are pending.

The specification has been amended to contain a reference to the United Kingdom application for which a benefit of priority is being claimed.

The phrase "for use in therapy" has been removed from claim 1. In addition, the proviso set forth in claim 2 has been incorporated into claim 1, claim 2 has been canceled, and claims 3 and 5 have each been amended to depend from claim 1 instead of claim 2.

Claims 7 and 8 have been amended to expressly recite the compounds of Examples 1-46 and Examples 47-49 respectively.

Use claim 10 has been canceled.

Claim 12 has been canceled, and the subject matter of claim 12 has been divided into two parts and presented in new method claims 13 and 14.

No new matter has been introduced by any of the changes to the specification and claims.

Respectfully submitted,

By: Kenneth R. Walton
Kenneth R. Walton, Reg. No. 32,951
Attorney for Applicants
MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
Tel.: (732) 594-3462

Date: July 2, 2004